|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
DE102004024617A1
(de)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EA200900741A1
(ru)
|
2006-11-27 |
2010-04-30 |
Айзис Фармасьютикалз, Инк. |
Способы лечения гиперхолестеринемии
|
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
|
US8435510B2
(en)
*
|
2007-08-08 |
2013-05-07 |
Sutter West Bay Hospitals |
Platelet derived growth factor receptor supports cytomegalovirus infectivity
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
EP2276455A2
(fr)
*
|
2008-04-22 |
2011-01-26 |
Centre National de la Recherche Scientifique |
Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
EP2405921A4
(en)
*
|
2009-01-26 |
2013-05-22 |
Protiva Biotherapeutics Inc |
COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION
|
|
WO2010111468A2
(en)
*
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
|
WO2011071535A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Mount Sinai School Of Medicine Of New York University |
Compositions and methods for inhibiting human host cell factors required for influenza virus replication
|
|
JP2013515697A
(ja)
*
|
2009-12-23 |
2013-05-09 |
マックスプランク−ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ |
インフルエンザ標的
|
|
EP2563921B1
(en)
*
|
2010-04-30 |
2016-11-23 |
Cellectis |
Method for modulating double-strand break-induced homologous recombination
|
|
CN109112126B
(zh)
*
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
EP2426216A1
(en)
*
|
2010-09-01 |
2012-03-07 |
Institut Gustave Roussy (IGR) |
Prognostic and/or predictive biomarkers and biological applications thereof
|
|
GB201018147D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Method of treatment
|
|
EP2633052B1
(en)
*
|
2010-10-27 |
2018-04-11 |
CuRNA, Inc. |
Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
|
|
EP2446883A1
(en)
*
|
2010-10-30 |
2012-05-02 |
University College Cork-National University of Ireland, Cork |
Treatment of inflammation
|
|
WO2012075114A2
(en)
*
|
2010-12-01 |
2012-06-07 |
Ablitech, Inc. |
Nucleic acid-polymer conjugates and uses thereof
|
|
WO2012122645A1
(en)
*
|
2011-03-11 |
2012-09-20 |
Sarissa Inc. |
Methods of treating cancer by inhibition of dna repair proteins
|
|
US20140227289A1
(en)
*
|
2011-05-13 |
2014-08-14 |
Stephen Michael Cohen |
Compounds and methods for treating insulin resistance syndrome
|
|
WO2013048345A1
(en)
*
|
2011-09-28 |
2013-04-04 |
Agency For Science, Technology And Research |
Methods and pharmaceutical compositions for treating cancer
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
CA2866392C
(en)
|
2012-03-30 |
2023-10-24 |
Washington University |
Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
|
WO2013157215A1
(ja)
*
|
2012-04-17 |
2013-10-24 |
国立大学法人山口大学 |
子宮体がん発症感受性の判定方法
|
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
|
BR112015022156A2
(pt)
|
2013-03-14 |
2017-11-14 |
Isis Pharmaceuticals Inc |
composições e métodos para modular a expressão de tau
|
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
|
EP2853596A1
(en)
|
2013-09-30 |
2015-04-01 |
IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) |
Protein phosphatase inhibitor
|
|
US20160333346A1
(en)
|
2014-01-17 |
2016-11-17 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid capable of inhibiting expression of beta-2gpi
|
|
JP6663149B2
(ja)
*
|
2014-07-04 |
2020-03-11 |
国立大学法人高知大学 |
膵がん細胞浸潤転移阻害剤
|
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
US20190071668A1
(en)
*
|
2015-07-08 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms
|
|
CA3005131A1
(en)
*
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of tuberous sclerosis complex
|
|
PT109454A
(pt)
*
|
2016-06-14 |
2017-12-14 |
Phyzat Biopharmaceuticals Lda |
Ácidos nucleicos de interferência e composições que os compreendem
|
|
MD3519572T2
(ro)
|
2016-09-29 |
2024-03-31 |
Biogen Ma Inc |
Compuși și procedee de reducere a expresiei Tau
|
|
TW201903149A
(zh)
|
2017-05-31 |
2019-01-16 |
日商協和醱酵麒麟有限公司 |
抑制apcs之表現的核酸
|
|
TN2019000308A1
(en)
|
2017-07-06 |
2021-05-07 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
|
|
CN111212909A
(zh)
*
|
2017-10-17 |
2020-05-29 |
箭头药业股份有限公司 |
用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
|
|
EP3710587A1
(en)
*
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
MY207352A
(en)
*
|
2018-03-21 |
2025-02-21 |
Regeneron Pharma |
17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
EP3689896A1
(en)
*
|
2019-01-31 |
2020-08-05 |
Universität Heidelberg |
Grk2 modulating mirnas
|
|
JP7574215B2
(ja)
|
2019-04-29 |
2024-10-28 |
ソレント セラピューティクス,エルエルシー |
MRGX2の阻害薬である3-アミノ-4H-ベンゾ[e][1,2,4]チアジアジン1,1-ジオキシド誘導体
|
|
JP2022535717A
(ja)
|
2019-05-24 |
2022-08-10 |
エンピリコ インク. |
アンジオポエチン様7(angptl7)関連疾患の処置
|
|
CN115397989A
(zh)
|
2020-02-18 |
2022-11-25 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
|
US20230190785A1
(en)
*
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
WO2022072356A1
(en)
*
|
2020-09-29 |
2022-04-07 |
Empirico Inc. |
Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
|
|
CA3200595A1
(en)
*
|
2020-11-13 |
2022-05-19 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor v (f5) irna compositions and methods of use thereof
|
|
GB202411150D0
(en)
*
|
2024-07-30 |
2024-09-11 |
Res & Innovation Uk |
Therapeutic antisense oligomers
|